JP2020531002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531002A5 JP2020531002A5 JP2020507675A JP2020507675A JP2020531002A5 JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5 JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- igg
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims 120
- 150000001413 amino acids Chemical group 0.000 claims 76
- 235000001014 amino acid Nutrition 0.000 claims 68
- 238000006467 substitution reaction Methods 0.000 claims 62
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 235000018102 proteins Nutrition 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 235000004279 alanine Nutrition 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 11
- 239000004473 Threonine Substances 0.000 claims 11
- 241000283073 Equus caballus Species 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 9
- 239000000833 heterodimer Substances 0.000 claims 9
- 241000282326 Felis catus Species 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 241000282465 Canis Species 0.000 claims 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 241000282324 Felis Species 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000282327 Felis silvestris Species 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545858P | 2017-08-15 | 2017-08-15 | |
| US62/545,858 | 2017-08-15 | ||
| PCT/IB2018/056142 WO2019035010A1 (en) | 2017-08-15 | 2018-08-15 | IGG VARIANTS FOR VETERINARY USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531002A JP2020531002A (ja) | 2020-11-05 |
| JP2020531002A5 true JP2020531002A5 (enExample) | 2021-09-30 |
Family
ID=65361820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507675A Pending JP2020531002A (ja) | 2017-08-15 | 2018-08-15 | 獣医学用ｉｇｇ ｆｃ変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12297272B2 (enExample) |
| EP (1) | EP3668536A4 (enExample) |
| JP (1) | JP2020531002A (enExample) |
| KR (1) | KR20200057701A (enExample) |
| CN (2) | CN119390821A (enExample) |
| AU (3) | AU2018318440A1 (enExample) |
| BR (1) | BR112020002871A2 (enExample) |
| CA (1) | CA3071337A1 (enExample) |
| MX (1) | MX2020001707A (enExample) |
| WO (1) | WO2019035010A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612112B (zh) | 2016-12-09 | 2024-03-29 | 阿卡斯通生物科学公司 | 胰岛素-fc融合物及使用方法 |
| CN119390821A (zh) | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| DK4186920T5 (da) | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| BR112021006977A2 (pt) * | 2018-10-18 | 2021-07-27 | Kindred Biosciences, Inc. | variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário |
| MX2021007680A (es) * | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| MX2021008144A (es) * | 2019-01-03 | 2021-10-13 | Invetx Inc | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. |
| CN113840831A (zh) * | 2019-03-20 | 2021-12-24 | 金德雷德生物科学股份有限公司 | 医用ngf拮抗剂 |
| JP2022542275A (ja) * | 2019-07-30 | 2022-09-30 | キンドレッド バイオサイエンシズ インコーポレイテッド | 動物用パルボウイルス抗体 |
| KR102865175B1 (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US20230348577A1 (en) | 2020-02-19 | 2023-11-02 | Adivo Gmbh | Modified fc regions |
| WO2021188631A1 (en) * | 2020-03-18 | 2021-09-23 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| BR112022020486A2 (pt) | 2020-04-10 | 2023-01-17 | Akston Biosciences Corp | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
| JP2023524643A (ja) * | 2020-04-22 | 2023-06-13 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための長時間作用性抗ｉｌ３１抗体 |
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| EP4149969A1 (en) | 2020-05-11 | 2023-03-22 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| AU2021306179A1 (en) | 2020-07-10 | 2023-03-02 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| WO2022046809A1 (en) * | 2020-08-24 | 2022-03-03 | The Trustees Of The University Of Pennsylvania | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| WO2023004406A2 (en) | 2021-07-23 | 2023-01-26 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| EP4380974A1 (en) * | 2021-08-06 | 2024-06-12 | Petmedix Ltd. | Antibody fc variants |
| KR20250130357A (ko) | 2022-12-27 | 2025-09-01 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체 (fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| WO2024155982A2 (en) | 2023-01-20 | 2024-07-25 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US7297482B2 (en) * | 1998-10-08 | 2007-11-20 | Rigel Pharmaceuticals, Inc. | Structurally biased random peptide libraries based on different scaffolds |
| WO2001047950A2 (en) * | 1999-12-23 | 2001-07-05 | Universite De Geneve | Basolateral sorting signal based on scf peptide and inhibitors thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| JP2004321100A (ja) | 2003-04-25 | 2004-11-18 | Rikogaku Shinkokai | ＩｇＧのＦｃ領域を含むタンパク質の変異体 |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EA011166B1 (ru) | 2004-12-22 | 2009-02-27 | Эли Лилли Энд Компани | Композиции слитых белков-аналогов glp-1 |
| WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| US8658174B2 (en) * | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EA201070121A1 (ru) * | 2007-07-10 | 2010-06-30 | Эли Лилли Энд Компани | Лекарственная форма, содержащая слитый белок glp-1-fc |
| AU2009329866B2 (en) * | 2008-12-23 | 2016-09-29 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein A |
| EP2413969A4 (en) | 2009-03-30 | 2012-09-05 | Boehringer Ingelheim Int | FUSION PROTEINS WITH DOG FC ELEMENTS |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| RU2012145183A (ru) * | 2010-03-29 | 2014-05-10 | Займворкс, Инк. | Антитела с повышенной или пониженной эффекторной функцией |
| US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| AU2012252153B2 (en) * | 2011-05-06 | 2016-07-07 | Zoetis Services Llc | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CA2835094C (en) * | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| US9353172B2 (en) | 2011-07-18 | 2016-05-31 | Arts Biologics A/S | Long acting biologically active luteinizing hormone (LH) compound |
| US9416168B2 (en) | 2011-07-19 | 2016-08-16 | The National Institute for Biotechnology in the Negev, Ltd | IL-17R-ECD mutants and methods of using same |
| US9790280B2 (en) | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| KR102052774B1 (ko) * | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| CN104159916A (zh) * | 2012-02-22 | 2014-11-19 | Nvip私人有限公司 | 肿瘤坏死因子受体融合蛋白及其使用方法 |
| ES2746103T3 (es) | 2012-04-30 | 2020-03-04 | Medimmune Llc | Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas |
| AU2013271564A1 (en) | 2012-06-06 | 2014-12-04 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| WO2014093387A1 (en) | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| KR20250152665A (ko) | 2013-07-31 | 2025-10-23 | 암젠 인크 | Ｆc-함유 폴리펩타이드의 안정화 |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| CA2932515C (en) | 2013-12-20 | 2023-08-01 | Intervet International B.V. | Caninized antibodies |
| US20170182154A1 (en) | 2014-01-22 | 2017-06-29 | Beijing Advaccine Biotechnology Co. Ltd | Vaccines with interleukin-17 as an adjuvant |
| CN106687135A (zh) | 2014-09-15 | 2017-05-17 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法 |
| ES2853823T3 (es) | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| EP3215524B1 (en) * | 2014-11-06 | 2021-01-13 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| EP3365011A1 (en) | 2015-10-19 | 2018-08-29 | Novartis AG | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| JP7008020B2 (ja) | 2015-12-18 | 2022-01-25 | インターベット インターナショナル ベー． フェー． | ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体 |
| JP6890135B2 (ja) | 2016-01-26 | 2021-06-18 | ディフェンシン セラピューティクス エーピーエス | 腸内微生物叢を調節するための方法 |
| EP3416984B1 (en) * | 2016-02-18 | 2021-03-31 | Elanco US Inc. | Chimeric canine anti-cd20 antibody |
| AU2017268469C1 (en) | 2016-05-20 | 2025-01-02 | President And Fellows Of Harvard College | Gene therapy methods for age-related diseases and conditions |
| CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| CN110799210A (zh) | 2016-12-02 | 2020-02-14 | 得克萨斯A&M大学系统 | 选择性消耗抗原特异性抗体的融合蛋白 |
| CA3059731A1 (en) * | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| CA3065553A1 (en) | 2017-06-18 | 2018-12-27 | Kindred Biosciences, Inc. | Il17a antibodies and antagonists for veterinary use |
| CN119390821A (zh) | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| DK4186920T5 (da) | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| US20220049002A1 (en) | 2018-09-14 | 2022-02-17 | Kindred Biosciences, Inc. | Anti-IL4 Receptor Antibodies for Veterinary Use |
| BR112021006977A2 (pt) | 2018-10-18 | 2021-07-27 | Kindred Biosciences, Inc. | variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| EP3892632A4 (en) | 2018-12-05 | 2022-08-17 | Bica Therapeutics Inc. | MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODIES |
| CN113423721A (zh) | 2018-12-12 | 2021-09-21 | 金德雷德生物科学股份有限公司 | 兽用促红细胞生成素类似物 |
| MX2021007680A (es) | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| MX2021008144A (es) | 2019-01-03 | 2021-10-13 | Invetx Inc | Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso. |
| CN113840831A (zh) | 2019-03-20 | 2021-12-24 | 金德雷德生物科学股份有限公司 | 医用ngf拮抗剂 |
| CN114599389A (zh) | 2019-08-22 | 2022-06-07 | 奇达拉治疗公司 | 变体fc结构域及其用途 |
| WO2021043127A1 (zh) | 2019-09-02 | 2021-03-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US20230242635A1 (en) | 2020-04-17 | 2023-08-03 | Zoetis Services Llc | Canine antibody variants |
| BR112022020631A2 (pt) | 2020-04-17 | 2022-11-29 | Zoetis Services Llc | Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula |
| JP2023524643A (ja) | 2020-04-22 | 2023-06-13 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための長時間作用性抗ｉｌ３１抗体 |
| CA3173927A1 (en) | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Il4/il13 receptor molecules for veterinary use |
| EP4149969A1 (en) | 2020-05-11 | 2023-03-22 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| WO2021251438A1 (ja) | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | エリスロポエチンポリペプチドを含む融合タンパク質 |
| WO2022005883A1 (en) | 2020-06-29 | 2022-01-06 | Zoetis Services Llc | Feline antibody variants for improving stability |
| AU2021306179A1 (en) | 2020-07-10 | 2023-03-02 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| EP4204013A4 (en) | 2020-08-26 | 2025-04-16 | Angiex, Inc. | ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USE THEREOF |
-
2018
- 2018-08-15 CN CN202411340586.6A patent/CN119390821A/zh active Pending
- 2018-08-15 US US16/638,402 patent/US12297272B2/en active Active
- 2018-08-15 CN CN201880064650.9A patent/CN111182915A/zh active Pending
- 2018-08-15 MX MX2020001707A patent/MX2020001707A/es unknown
- 2018-08-15 AU AU2018318440A patent/AU2018318440A1/en not_active Abandoned
- 2018-08-15 EP EP18846242.8A patent/EP3668536A4/en active Pending
- 2018-08-15 WO PCT/IB2018/056142 patent/WO2019035010A1/en not_active Ceased
- 2018-08-15 BR BR112020002871-1A patent/BR112020002871A2/pt unknown
- 2018-08-15 KR KR1020207005513A patent/KR20200057701A/ko not_active Ceased
- 2018-08-15 JP JP2020507675A patent/JP2020531002A/ja active Pending
- 2018-08-15 CA CA3071337A patent/CA3071337A1/en active Pending
-
2023
- 2023-09-06 AU AU2023226676A patent/AU2023226676B2/en active Active
-
2025
- 2025-08-22 AU AU2025220819A patent/AU2025220819A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531002A5 (enExample) | ||
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| JP7748393B2 (ja) | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| US12351622B2 (en) | Modified product of Fc domain of antibody | |
| JP7231553B2 (ja) | Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用 | |
| JP5199876B2 (ja) | 一価ＩｇＧを生成するための方法 | |
| US10287336B2 (en) | Feline erythropoietin receptor agonists | |
| JP2017527272A5 (enExample) | ||
| US20130121959A1 (en) | Il-22-fc and hepcidin activity | |
| JP2019511457A5 (enExample) | ||
| EP4166574A1 (en) | Fusion protein containing erythropoietin polypeptide | |
| CN117999289A (zh) | 具有延长的半衰期的抗体和IgG融合蛋白 |